ACE1831

Acepodia Biotech, Inc. · Phase 1 active Small molecule

At a glance

Generic name	ACE1831
Sponsor	Acepodia Biotech, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease (PHASE1, PHASE2)
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE） (NA)
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ACE1831 CI brief — competitive landscape report
ACE1831 updates RSS · CI watch RSS
Acepodia Biotech, Inc. portfolio CI